The exercise of warrants leading to $4.8 million in gross proceeds for Agile Therapeutics is likely to be viewed positively by investors as it increases the company's cash reserves. This additional liquidity can be crucial for funding ongoing operations or future growth initiatives, potentially making the company more attractive to investors in the short term.